Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis

Abstract

Background In randomised controlled trials, fixed-dose combination treatments (or polypills) have been shown to reduce a composite of cardiovascular disease outcomes in primary prevention. However, whether or not aspirin should be included, effects on specific outcomes, and effects in key subgroups are unknown.Methods We did an individual participant data meta-analysis of large randomised controlled trials (each with ≥1000 participants and ≥2 years of follow-up) of a fixed-dose combination treatment strategy versus control in a primary cardiovascular disease prevention population. We included trials that evaluated a fixed-dose combination strategy of at least two blood pressure lowering agents plus a statin (with or without aspirin), compared with a control strategy (either placebo or usual care). The primary outcome was time to first occurrence of a composite of cardiovascular death, myocardial infarction, stroke, or arterial revascularisation. Additional outcomes included individual cardiovascular outcomes and death from any cause. Outcomes were also evaluated in groups stratified by the inclusion of aspirin in the fixed-dose treatment strategy, and effect sizes were estimated in prespecified subgroups based on risk factors. Kaplan-Meier survival curves and Cox proportional hazard regression models were used to compare strategies.Findings Three large randomised trials were included in the analysis (TIPS-3, HOPE-3, and PolyIran), with a total of 18 162 participants. Mean age was 63·0 years (SD 7·1), and 9038 (49·8%) participants were female. Estimated 10-year cardiovascular disease risk for the population was 17·7% (8·7). During a median follow-up of 5 years, the primary outcome occurred in 276 (3·0%) participants in the fixed-dose combination strategy group compared with 445 (4·9%) in the control group (hazard ratio 0·62, 95% CI 0·53-0·73, p<0·0001). Reductions were also observed for the separate components of the primary outcome: myocardial infarction (0·52, 0·38-0·70), revascularisation (0·54, 0·36-0·80), stroke (0·59, 0·45-0·78), and cardiovascular death (0·65, 0·52-0·81). Significant reductions in the primary outcome and its components were observed in the analyses of fixed-dose combination strategies with and without aspirin, with greater reductions for strategies including aspirin. Treatment effects were similar at different lipid and blood pressure levels, and in the presence or absence of diabetes, smoking, or obesity. Gastrointestinal bleeding was uncommon but slightly more frequent in the fixed-dose combination strategy with aspirin group versus control (19 [0·4%] vs 11 [0·2%], p=0·15). The frequencies of haemorrhagic stroke (10 [0·2%] vs 15 [0·3%]), fatal bleeding (two [<0·1%] vs four [0·1%]), and peptic ulcer disease (32 [0·7%] vs 34 [0·8%]) were low and did not differ significantly between groups. Dizziness was more common with fixed-dose combination treatment (1060 [11·7%] vs 834 [9·2%], p<0·0001).Interpretation Fixed-dose combination treatment strategies substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularisation, and cardiovascular death in primary cardiovascular disease prevention. These benefits are consistent irrespective of cardiometabolic risk factors.Funding Population Health Research Institute.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)01827-4

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 151

Metadata

Authors
Joseph, P., Roshandel, G., Gao, P., Pais, P., Lonn, E., Xavier, D., Avezum, A., Zhu, J., Liu, L., Sliwa, K., Gamra, H., Bangdiwala, S. I., Teo, K., Diaz, R., Dans, A., Lopez-Jaramillo, P., Prabhakaran, D., Castellano, J. M., Fuster, V., Rodgers, A., Huffman, M. D., Bosch, J., Dagenais, G. R., Malekzadeh, R., & Yusuf, S.
Affiliations
  • Population Health Research Institute (CA)
  • Golestan University of Medical Sciences (IR)
  • St. John's Research Institute (IN)
  • St.John's Medical College Hospital (IN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • University of Cape Town (ZA)
  • University of Monastir (TN)
  • University of the Philippines Manila (PH)
  • Public Health Foundation of India (IN)
  • Instituto de Salud Carlos III (ES)
  • The George Institute for Global Health (AU)
  • Northwestern University (US)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
  • Shariati Hospital (IR)
Corresponding author
Yusuf, Salim
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-09
Volume
398
Issue
10306
Pages
1133-1146
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3196464088
Cited by
151
References
24
Citations by year
2026: 8 · 2025: 24 · 2024: 34 · 2023: 42 · 2022: 34 · 2021: 9
FWCI
6.07
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords
fixed-dose combination, polypill, aspirin, primary prevention, cardiovascular disease, statins, blood pressure lowering agents, cardiovascular mortality, myocardial infarction, stroke, revascularization, subgroup analysis, cardiovascular risk stratification
MeSH terms
Aspirin, Blood Pressure, Cardiovascular Diseases, Drug Therapy, Combination, Female, Gastrointestinal Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Primary Prevention, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01827-4
The paper
Joseph, P., Roshandel, G., Gao, P., Pais, P., Lonn, E., Xavier, D., Avezum, A., Zhu, J., Liu, L., Sliwa, K., Gamra, H., Bangdiwala, S. I., Teo, K., Diaz, R., Dans, A., Lopez-Jaramillo, P., Prabhakaran, D., Castellano, J. M., Fuster, V., . . . Yusuf, S. (2021). Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(21)01827-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.